Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
By William Pao, Vincent A. Miller, K. Politi, Gregory Riely, R. Somwar, M. Zakowski, M. Kris, H. Varmus. PLoS Medicine, 2005
3,566 citations recorded by the source corpus.
Background Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR). Despite initial responses, patients eventually progress by unknown mechanisms of “acquired” resistance. Methods and Findings We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain. Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation. This mutation was not detected in untreated tumor samples. Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs. Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib. Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec). Conclusion In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug. This observation should help guide the search for more effective therapy against a specific subset of lung cancers.
Subfields: Hematology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/4c8e50e8d66b0ce42217ec01d5b277c699c09f32
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC (2010, background): “Secondary mutations in EGFR itself, including the EGFR T790M ‘‘gatekeeper’’ mutation is observed in 50% of resistance cases, and amplification of the MET oncogene is observed in 20% of resistance cases (Balak et al., 2006; Bean et al., 2007; Engelman et al., 2007b; Kobayashi et al., 2005; Kosaka et ”
- Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity (2020, background): “Gefitinib Selective EGFR inhibitor (ATP competitive) EGFR T790M mutation [32,33]; Gene amplification (e.”
- Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation (2010, methodology): “Testing for the T790M mutation was then performed using standard methodologies (12, 23).”
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer (2012, positive): “In contrast, EGFR T790M mutations confer impaired growth compared with cells carrying EGFR-activating mutations alone (25).”
- The resurgence of covalent drugs (2011, background): “For example, approximately 50% of patients with non-small-cell lung carcinoma (NSCLC) who initially responded to reversible EGFR inhibitors relapsed owing to the emergence of tumour cells that express EGFR with mutations at T790M and/or L858R in the ATP binding sit”
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors (2011, background): “They have identified several resistance mechanisms, two of which—EGFR mutation T790M (6, 7) andMET amplification (8, 9)—have been validated in the clinic.”